Context Therapeutics Inc. 6K9.F Stock
Context Therapeutics Inc. Price Chart
Context Therapeutics Inc. 6K9.F Financial and Trading Overview
| Context Therapeutics Inc. stock price | 1.79 EUR |
| Previous Close | 1.12 EUR |
| Open | 1.1 EUR |
| Bid | 1.1 EUR x N/A |
| Ask | 1.13 EUR x N/A |
| Day's Range | 1.1 - 1.1 EUR |
| 52 Week Range | 0.42 - 2.2 EUR |
| Volume | 1K EUR |
| Avg. Volume | 194 EUR |
| Market Cap | 17.73M EUR |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
6K9.F Valuation Measures
| Enterprise Value | -11855342 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.61111116 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Context Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -41.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.2 EUR |
| 52 Week Low | 0.42 EUR |
| 50-Day Moving Average | 0.63 EUR |
| 200-Day Moving Average | 0.91 EUR |
6K9.F Share Statistics
| Avg. Volume (3 month) | 194 EUR |
| Avg. Daily Volume (10-Days) | 100 EUR |
| Shares Outstanding | 15.97M |
| Float | 10.99M |
| Short Ratio | N/A |
| % Held by Insiders | 6.82% |
| % Held by Institutions | 23.80% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.64% |
| Return on Equity (ttm) | -47.77% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -17705920 EUR |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.77M EUR |
| Total Cash Per Share (mrq) | 1.87 EUR |
| Total Debt (mrq) | 31.67K EUR |
| Total Debt/Equity (mrq) | 0.11 EUR |
| Current Ratio (mrq) | 9.861 |
| Book Value Per Share (mrq) | 1.8 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15457408 EUR |
| Levered Free Cash Flow (ttm) | -10061297 EUR |
Profile of Context Therapeutics Inc.
| Country | Germany |
| State | PA |
| City | Philadelphia |
| Address | 2001 Market Street |
| ZIP | 19103 |
| Phone | 267 225 7416 |
| Website | https://www.contexttherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9 |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Context Therapeutics Inc. Stock
What is a current 6K9.F stock price?
Context Therapeutics Inc. 6K9.F stock price today per share is 1.79 EUR.
How to purchase Context Therapeutics Inc. stock?
You can buy 6K9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Context Therapeutics Inc.?
The stock symbol or ticker of Context Therapeutics Inc. is 6K9.F.
Which industry does the Context Therapeutics Inc. company belong to?
The Context Therapeutics Inc. industry is Biotechnology.
How many shares does Context Therapeutics Inc. have in circulation?
The max supply of Context Therapeutics Inc. shares is 76.26M.
What is Context Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Context Therapeutics Inc. PE Ratio is now.
What was Context Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Context Therapeutics Inc. EPS is -1.4 EUR over the trailing 12 months.
Which sector does the Context Therapeutics Inc. company belong to?
The Context Therapeutics Inc. sector is Healthcare.